FFC#25/2014

Targeting PI3Kγ scaffold function to activate airway CFTR, limit lung inflammation and promote bronchorelaxation in cystic fibrosis

FFC#25/2014

Targeting PI3Kγ scaffold function to activate airway CFTR, limit lung inflammation and promote bronchorelaxation in cystic fibrosis

PRINCIPAL INVESTIGATOR

Emilio Hirsch (Dip. di Biotecnologie Molecolari e Scienze per la Salute, Università di Torino, Centro di Biotecnologia Molecolare)

Partner

Carlo Laudanna (Dip. di Patologia e Diagnostica, Università di Verona, Lab. di Traffico Cellulare e Trasduzione del segnale)

RESEARCHERS

7

CATEGORY

AREA 4 Lung inflammation

DURATION

1 year

GOAL

€ 76.000

RESULTS

Researchers’ preliminary data indicate that, in airway epithelial cells, PI3Kγ primarily serves as a scaffold protein that anchors cAMP-degrading enzymes (PDE) to their activator, protein kinase A (PKA) and ultimately promotes cAMP clearance. A compound disrupting PI3Kγ scaffold function (Patent pending N°TO2014A001105) lowers PDE4 activity and enhances cAMP-mediated phosphorylation and activation of F508del CFTR. Intriguingly, this
molecule also promotes cAMP-mediated inactivation of leukocytes and cAMP-dependent relaxation of airway smooth muscle. Further results are expected in the extension project FFC#23/2015.

OTHER RESULTS

FFC #3/2024

Two molecules are effective in activating Heat Shock Proteins and enhancing the action of CFTR correctors with the F508del mutation in vitro.

FFC#5/2024

Some peptide nucleic acids (PNAs) re-sensitise Pseudomonas aeruginosa to the antibiotic meropenem in vitro and reduce its virulence.

FFC#1/2023

Tezacaftor, one of the components of Kaftrio, induces an accumulation of dihydroceramides both in vitro and in vivo in animal models